FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 2, 2002
--------------
TRIANGLE PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-21589 56-1930728
----------------------------- ---------------- -------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 493-5980
--------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
On August 2, 2002, Triangle Pharmaceuticals entered into a Stock Voting
Agreement with each stockholder who was a signatory thereto, a copy of which is
attached hereto as Exhibit 10.1. and is incorporated herein by reference
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits. The following documents are filed as exhibits to this
Report:
10.1 Stock Voting Agreement dated August 2, 2002 between Triangle
Pharmaceuticals, Inc. and each stockholder who is a
signatory thereto.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Triangle Pharmaceuticals, Inc.
------------------------------------------------
(Registrant)
August 28, 2002 /s/ Chris A. Rallis
------------------------------ ------------------------------------------------
Date (Signature)
Name: Chris A. Rallis
Title: President & Chief Operating Officer